Home / PET

PET

April 28, 2025

Total body PET imaging: the changing radionuclide imaging landscape in the UK

Non-invasive radionuclide imaging has transformed clinical practice through enabling earlier diagnosis than before, more comprehensive staging, and monitoring of disease progression and therapy response. The quantitative nature of PET and widespread availability of standard radiopharmaceuticals, in particular [18F]FDG, have contributed to PET’s success. However, until recently, in order to capture information ‘from eyes to thighs’, […]

Professor Alexander Hammers; Dr Samantha Terry

King's College London

Read Article

April 28, 2025

An overview of CZT technology

The gamma camera has been a stalwart of nuclear medicine for many years. First described in 1958 by Hal Anger, the gamma camera is still the most used instrument for nuclear medicine imaging studies. While the transition to rotating tomographic SPECT systems and the incorporation of CT for SPECT attenuation correction and localisation has changed […]

Professor John C Dickson

University College London Hospitals NHS Foundation Trust

Read Article

October 16, 2024

Motion in myocardial perfusion PET

Myocardial perfusion PET is a well established technique for assessing obstructive coronary artery and coronary microvascular diseases. It has been shown to be superior to SPECT imaging in image quality, prognostic information, scan time and lower radiation dose for both the patient and operators. Through the creation of dynamic images, PET also provides the ability […]

Dr Ian Armstrong

Manchester University NHS Foundation Trust

Read Article

October 16, 2024

PSMA PET scanning in practice

Prostate cancer is the second most common cancer in the world, predicted to rise by 15% by 2025, while detection in late stage disease increased from 3.9% to 8.2% over the past decade in the USA. Primary investigations for clinical diagnosis and staging of prostate cancer include blood tests, biopsy and imaging techniques such as […]

Rayjanah Allie, Dr Dimitris Priftakis, Professor Jamshed Bomanji

University College London Hospitals NHS Foundation Trust

Read Article

July 17, 2024

Can AI predict survival from pre-treatment PET images for patients with oesophageal cancer?

Oesophageal cancer is one of the leading causes of cancer death in the UK, with a 10-year survival rate of just 12%. Despite advances in diagnosis and curative treatment, the number of deaths from oesophageal cancer remains high, with over 50% of patients diagnosed with stage IV (incurable) disease. It is potentially curable with surgery […]

Dr Nicholas Vennart

South Tyneside and Sunderland NHS Foundation Trust

Read Article

July 17, 2024

Introducing positron emission particle tracking into the biomedical field

Positron emission particle tracking (PEPT) is an imaging methodology that offers high resolution visualisation on the trajectory of a single radiolabelled particle as it moves within a given system. Diverging from PET, where g-rays from positron annihilation serve to image radiolabelled tracers (radiopharmaceuticals), PEPT leverages the fact that all emitted photons originate from a singular […]

Juan Pellico, Rafael T M Rosales

King's College London, St Thomas' Hospital

Read Article

July 17, 2024

Total body PET: leveraging new technology and UK infrastructure to help improve patient outcomes

PET is a compelling technology in the fight against some of the most common causes of death. PET scanners sensitively measure biological and biochemical processes in the body by measuring the location of radioactive molecules (radiotracers) following their injection into patients. However, traditional PET technologies can only image part of the body, meaning that multiple […]

Dr Juliana Maynard

Medicines Discovery Catapult; National PET Imaging Platform

Read Article

July 12, 2023

Non-FDG PET tracers in oncology: the story so far

The role of radionuclide molecular imaging in oncology with 2-deoxy-2-[fluorine-18] fluoro-D-glucose (18F-FDG) is well established. There is ample evidence to support the role of 18F-FDG PETCT in various clinical scenarios and cancer types. However, there has been a phenomenal expansion in non-FDG PET radiopharmaceuticals for use in clinical oncology. 68Ga is a well established radionuclide […]